Mon panier

GMP Human GM-CSF Protein

  • Premium grade (Pre-GMP) version GMF-H4214 is now available for seamless transition.
Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
GMP-GMFH28-50ug
$510.00
GMP-GMFH28-1mg (50ug X 20)
$4895.00
GMP-GMFH28-10mg (50ug X 200)
$34265.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • GMP Platform Advantages

    1. Quality Assurance: Global QMS with comprehensive and stringent QC release criteria.
    2. End-to-End GMP Compliance: Full manufacturing and QC under a cGMP system.
    3. Comprehensive Control of Adventitious Agents: Stringent biosafety from cell banks to final release.
    4. Comprehensive Regulatory Support: Includes RSF and DMF to meet global requirements.
    5. Resilient Supply Chain: Intelligent modular facilities ensure a stable global supply.
    6. Professional Support: Extensive manufacturing and application expertise to accelerate development.
  • Source

    GMP Human GM-CSF Protein (GMP-GMFH28) is expressed from human 293 cells (HEK293). It contains AA Ala 18 - Glu 144 (Accession # P04141).

    Predicted N-terminus: Ala 18

    Request for sequence
  • Molecular Characterization

    GM-CSF Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries no "tag".

    The protein has a calculated MW of 14.5 kDa. The protein migrates as 25 kDa±3 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 10 EU/mg, tested by the LAL method in compliance with USP <85> and Ph. Eur. 2.6.14.

  • Host Cell Protein

    <0.5 ng/µg of protein tested by ELISA.

  • Host Cell DNA

    <0.02 ng/μg of protein tested by qPCR.

  • Sterility

    Sterility testing was performed using the membrane filtration method in compliance with USP <71> and Ph. Eur. 2.6.1.

  • Mycoplasma

    Negative

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with protectants.

    Contact us for customized product form or formulation.

  • Vial Specification

    2R (13 mm neck finish)

  • Shipping

    This product is supplied and shipped with blue ice, please inquire the shipping cost.

  • Storage

    Upon receipt, store it immediately at -20°C or lower for long term storage.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 5 years in lyophilized state;
    2. -70°C for 12 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    GM-CSF SDS-PAGE

    GMP Human GM-CSF Protein on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).

  • Bioactivity-CELL BASE

     GM-CSF CELL

    GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) stimulates proliferation of TF-1 cells. The specific activity of GMP Human GM-CSF Protein is > 5.00ⅹ10^6 IU/mg, which is calibrated against human GM-CSF WHO International Standard (NIBSC code: 88/646) (QC tested).

    Protocol
  •  GM-CSF CELL

    GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) exhibits superior activity compared to commercially available product.

  • Application Data

     GM-CSF APPLICATION DATA

    Schematic diagram of monocyte differentiation into dendritic cells.

  •  GM-CSF APPLICATION DATA

    Detection of differentiation markers during monocyte‑to‑DC differentiation.
    Representative histograms showing surface expression of CD14, CD83, HLA‑DR, CD80, and CD86 on monocytes, immature monocyte‑derived DCs (imMo‑DCs), and mature Mo‑DCs (mMo‑DCs) cultured in either ACRO medium or Company X medium. Both media effectively induced differentiation of monocytes into DCs, as evidenced by marked upregulation of CD83, HLA‑DR, CD80, and CD86 and downregulation of CD14. Compared with imMo‑DCs, mMo‑DCs showed further increases in the expression of CD80, CD83, and CD86. Marker‑specific staining is shown in red (ACRO) or blue (Company X), and isotype controls are shown in gray. Histograms are from one representative experiment (A). Corresponding mean fluorescence intensity (MFI) values for each marker from three technical replicates. Data are presented as mean ± SD (B).

  • Bioactivity-Stability

     GM-CSF STABILITY

    Cell-based assay demonstrates that the lyophilized GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) is stable at 37°C for 35 days.

  •  GM-CSF STABILITY

    Cell-based assay demonstrates that the reconstituted GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) is stable at 4°C for 180 days.

  •  GM-CSF STABILITY

    Cell-based assay demonstrates that the reconstituted GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) is stable at 37℃ for 24 hours.

  •  GM-CSF STABILITY

    Cell-based assay demonstrates that the reconstituted GMP Human GM-CSF Protein (Cat. No. GMP-GMFH28) is stable after 3 freeze-thaw cycles.

  •  GM-CSF STABILITY

    Cell-based assay demonstrates batch-to-batch consistency between Acro's GMP and PG GM-CSF.

Avis des utilisateurs
Publier un commentaire

Introduction de fond

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is also known as Colony stimulating factor 2 (granulocyte-macrophage), is a cytokine initially characterized by its ability to induce colonies of granulocytes and macrophages from myeloid progenitor cells, and is secreted by macrophages, T cells, mast cells, endothelial cells and fibroblasts. GM-CSF is a cytokine that functions as a white blood cell growth factor. GM-CSF stimulates stem cells to produce granulocytes (neutrophils, eosinophils, and basophils) and monocytes. Monocytes exitthe circulation and migrate into tissue, whereupon they mature into macrophages and dendritic cells. Thus, it is part of the immune/inflammatory cascade, by which activation of a small number of macrophages can rapidly lead to an increase in their numbers, a process crucial for fighting infection. The active form of the protein is found extracellularly as a homodimer. Human GM-CSF glycosylated in its mature form. As a part of the immune/inflammatory cascade, GM-CSF promotes Th1 biased immune response, angiogenesis, allergic inflammation, and the development of autoimmunity, and thus worthy of consideration for therapeutic target. GM-CSF has also recently been evaluated in clinical trials for its potential as a vaccine adjuvant in HIV-infected patients. The preliminary results have been promising. GM-CSF is also used as a medication to stimulate the production of white blood cells following chemotherapy.

Déclaration importante

  • MANUFACTURING SPECIFICATIONS

    ACROBiosystems GMP grade products are produced under a quality management system and in compliance with relevant guidelines: Ph. Eur General Chapter 5.2.12 Raw materials of biological origin for the production of cell-based and gene therapy medicinal products; USP<92>Growth Factors and Cytokines Used in Cell Therapy Manufacturing; USP<1043>Ancillary Materials for Cell, Gene, and Tissue-Engineered Products; ISO/TS 20399-1:2018, Biotechnology - Ancillary Materials Present During the Production of Cellular Therapeutic Products.

    ACROBiosystems Quality Management System Contents:

    1. GMP-certified facility (compliance with FDA cGMP, EMA GMP, ICH, ISO9001/13485/MDSAP, and certified by third-party SGS, UL, and RX360)
    2. Animal origin-free materials, equipments, and facilities
    3. Materials sourced only from approved suppliers
    4. ISO 5 cleanrooms and automatic filling equipment
    5. Professional quality personnel and training programs
    6. Validated analytical testing methods in accordance with the ICH guidelines
    7. Safety Testing (Sterility, Mycoplasma, etc): compliant with USP, EP, etc
    8. In-depth stability studies
    9. Fully batch production and control records
    10. Equipment maintenance and calibration

    Request For Regulatory Support Files (RSF)

    ACROBiosystems provide rigorous quality control tests (fully validated equipment, processes and test methods) on our GMP grade products to ensure that they meet stringent standards in terms of purity, safety, activity and inter-batch stability, and each bulk QC lot mainly contains the following specific information:

    1. SDS-PAGE
    2. Protein content
    3. Endotoxin level
    4. Residual Host Cell DNA content
    5. Residual Host Cell Protein content
    6. Biological activity analysis
    7. Microbial testing
    8. Mycoplasma testing
    9. In vitro virus assay
    10. Residual moisture
    11. Batch-to-batch consistency

  • ACROBIOSYSTEMS - LEGAL NOTICES FOR GMP GRADE PRODUCTS

    1. PRODUCT USE RESTRICTIONS & PROHIBITIONS

    • 1.1 ACROBiosystems ("ACRO") GMP grade products ("Products") are designed for research, manufacturing use or ex vivo use.
    • 1.2 Products are NOT intended for diagnostic purposes or for direct or indirect administration into humans.
    • 1.3 Purchaser shall not market, distribute, or resell Products obtained from ACRO without ACRO's prior written consent.

    2. REVERSE ENGINEERING PROHIBITED & CONFIDENTIALITY

    • 2.1 Purchaser shall not reverse-engineer, decompile, disassemble, sequence, analyze via bioinformatics, or otherwise attempt to discover the structure, sequence, composition, construction, manufacturing process, or any trade secret embodied in the Products. Purchaser shall not permit any third party to undertake such activities.
    • 2.2 All specifications, data, and know-how related to the Products provided by ACRO are ACRO's confidential information and shall be protected accordingly.

    3. LIMITED WARRANTY & DISCLAIMERS

    • 3.1 ACRO warrants solely that Products will conform to their published specifications when used under normal, specified laboratory/manufacturing conditions and within their labeled expiration date. THIS IS THE ONLY WARRANTY PROVIDED.
    • 3.2 Purchaser assumes ALL risk and responsibility for:
      (a) Determining the suitability of Products for Purchaser's intended application(s).
      (b) Obtaining any necessary regulatory approvals or intellectual property licenses for Purchaser's use.
      (c) Compliance with all applicable laws, regulations (including but not limited to cGMP/GLP where claimed), and industry standards.
      (d) Conducting all necessary quality control, safety, efficacy, and validation testing of Products within Purchaser's process or final product.
      (e) Proper storage, handling, and use of Products according to ACRO's instructions.
    • 3.3 ACRO EXPRESSLY DISCLAIMS ALL OTHER WARRANTIES, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHERWISE, INCLUDING BUT NOT LIMITED TO: (A) WARRANTIES OF MERCHANTABILITY; (B) WARRANTIES OF FITNESS FOR A PARTICULAR PURPOSE; (C) WARRANTIES OF NON-INFRINGEMENT; AND (D) WARRANTIES ARISING FROM COURSE OF DEALING OR USAGE OF TRADE.

    4. LIMITATION OF LIABILITY

    • IN NO EVENT SHALL ACRO, ITS AFFILIATES, OR SUPPLIERS BE LIABLE FOR ANY OF THE FOLLOWING, HOWSOEVER ARISING (WHETHER IN CONTRACT, TORT (INCLUDING NEGLIGENCE), STRICT LIABILITY, STATUTE, OR OTHERWISE):
      (a) LOST PROFITS, LOST REVENUE, LOST SAVINGS, LOSS OF USE, LOSS OF DATA, BUSINESS INTERRUPTION, OR ANY OTHER INDIRECT, INCIDENTAL, SPECIAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES.
      (b) ANY DIRECT DAMAGES, COSTS, OR EXPENSES EXCEEDING THE AMOUNT PAID BY PURCHASER FOR THE SPECIFIC PRODUCT(S) GIVING RISE TO THE CLAIM.
      (c) DAMAGES ARISING FROM: (i) MISUSE, ABUSE, OR UNAUTHORIZED MODIFICATION OF PRODUCTS; (ii) USE BEYOND THE EXPIRATION DATE; (iii) IMPROPER STORAGE OR HANDLING; (iv) ACCIDENTAL DAMAGE; (v) FAILURE TO CONDUCT ADEQUATE VALIDATION OR TESTING BY PURCHASER; (vi) INFRINGEMENT CLAIMS RELATED TO PURCHASER'S USE; OR (vii) THE COST OF PROCURING SUBSTITUTE GOODS OR SERVICES.
      (d) ANY PERSONAL INJURY, DEATH, OR DAMAGE TO TANGIBLE PROPERTY TO THE EXTENT PERMITTED BY LAW.

    5. END USER ACKNOWLEDGEMENT & COMPLIANCE

    • 5.1 By accepting, opening, or using the Products, the End User (Purchaser or its downstream recipient) agrees to be irrevocably bound by all terms herein.
    • 5.2 End User explicitly acknowledges the Products are NOT FOR HUMAN ADMINISTRATION and agrees not to use them in any in vivo human application, directly or indirectly.
    • 5.3 End Users unwilling to accept these terms must immediately: (a) cease all use; (b) notify ACRO or their supplier; and (c) return the unopened, unused Products.
    • 5.4 ACRO reserves the right to audit End User's compliance with these restrictions upon reasonable notice.

    ACRO has the right, at its sole discretion, to modify, add or remove any terms herein without notice to Purchaser and/or End User. Any changes to these terms are effective immediately following the updating of such changes on ACRO’s website or published specifications or product-related documents.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    Macrophage colony stimulating factor 2

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    9 Détails

  • Étape de développement la plus élevée:

    NDA/BLA

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte
  • Déclaration importante